Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been given an average rating of “Buy” by the twenty-four brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and twenty have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $182.49.
A number of analysts have recently weighed in on JAZZ shares. Seaport Global Securities set a $175.00 price objective on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 6th. Piper Jaffray Companies reissued a “buy” rating and issued a $201.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, March 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, April 30th. Bank of America raised their price objective on Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 20th. Finally, B. Riley raised their price objective on Jazz Pharmaceuticals from $206.00 to $211.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th.
Jazz Pharmaceuticals traded up $1.42, hitting $177.23, during midday trading on Friday, according to MarketBeat. 406,435 shares of the company traded hands, compared to its average volume of 471,219. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $10.68 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.91 and a beta of 0.96. Jazz Pharmaceuticals has a 52 week low of $128.58 and a 52 week high of $179.19.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $2.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.78 by $0.20. The firm had revenue of $444.61 million during the quarter, compared to analysts’ expectations of $435.69 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. The business’s quarterly revenue was up 18.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.31 EPS. equities analysts predict that Jazz Pharmaceuticals will post 11.65 earnings per share for the current fiscal year.
In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $170.04, for a total transaction of $850,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $150.01, for a total value of $150,010.00. Following the transaction, the chief executive officer now owns 293,542 shares of the company’s stock, valued at approximately $44,034,235.42. The disclosure for this sale can be found here. Insiders sold a total of 24,179 shares of company stock valued at $3,965,975 in the last 90 days. 4.30% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 18.4% during the 4th quarter. Bank of New York Mellon Corp now owns 1,760,547 shares of the specialty pharmaceutical company’s stock valued at $237,057,000 after buying an additional 274,121 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Jazz Pharmaceuticals by 2.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,244,800 shares of the specialty pharmaceutical company’s stock valued at $167,612,000 after buying an additional 28,700 shares during the last quarter. FIL Ltd raised its stake in shares of Jazz Pharmaceuticals by 1.0% during the 1st quarter. FIL Ltd now owns 908,737 shares of the specialty pharmaceutical company’s stock valued at $137,211,000 after buying an additional 8,935 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 29.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 755,623 shares of the specialty pharmaceutical company’s stock valued at $101,745,000 after buying an additional 171,174 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $577,000. Institutional investors and hedge funds own 88.91% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.